Medytox said on the 12th that it posted 60.7 billion won in consolidation sales in the first quarter of this year. That was down 5% from a year earlier. Operating profit was 7.4 billion won, and net profit was 7.9 billion won. Those rose 35% and 136%, respectively, from a year earlier.
Botulinum toxin formulations (Botox) Medytoxin, NEWLUX, and Coretox generated profits at home and abroad. These are made by extracting a toxic protein from the botulinum bacterium. When injected into the skin, they paralyze muscles, temporarily smoothing fine wrinkles.
The chin fat-reduction injection Newbeauje had part of the batches released at the end of March reflected in first-quarter results. Medytox plans to strengthen the Newbeauje business. A company official said, "We will push to expand the global market for next-generation products."